S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

3 Downgrades You Might Want To Buy

Tuesday, July 13, 2021 | Thomas Hughes
3 Downgrades You Might Want To Buy

The Bar Has Been Lowered For These Strong Companies

In our never-ending quest to root out the most interesting, and the most lucrative, investment stories on the market we've run across three downgrades we think you might want to buy. These downgrades aren't typically the kind of thing we want to see happening in stocks that we like but think these will ultimately turn into buying opportunities. The number one trend in earnings since the pandemic even began has been an underestimation. The analysts underestimated the resilience of the US economy during the shutdown and have grossly underestimated the strength of the rebound in the time since. The only question for us is how much better than expected these companies will report when it's their turn to report second-quarter earnings.

Big Lots Is The Most Underestimated Retail Stock On The Market

Big Lots (NYSE: BIG) has been hands down one of the biggest winners from the pandemic and yet it still gets no love from the analysts. The analysts have been only neutral on this stock since well before the pandemic began and now it looks like the sentiment is going to turn a little bit sourer. Bank of America put the stock on a list of underperform-rated small and mid-cap stocks with downside potential that we just don't see happening. In Bank of America’s view, the receding impact of stay-at-home trends and stimulus money is more than enough to offset strong management and the company’s nationwide rationalization. 

Called Operation North Star, the rationalization is, in our opinion, the most important factor in this company's turnaround so we definitely disagree with this analyst opinion. The consensus price target of $61.50 assumes this stock is fairly valued but there is a caveat, the analyst activity has been very light over the past year and the most recent price targets skew towards $75 and the high end of the range. Valued at only 9X its earnings, we think this stock should be trading well over $100 and with a much higher valuation. Don't forget it is a high-quality dividend grower with a 1.9% yield and most other retailers are valued at nearly double the amount.

Three Downgrades You Might Want To Buy

Bernstein Makes A Hard Call On Charter Communications

Bernstein downgraded Charter Communications (NASDAQ: CHTR) to Market Perform from Outperform but not because the company's business is flagging. The problem here is that competition, especially from T-Mobile, is going to cut into the growth Outlook and that means downward revisions to consensus targets. Notably, Bernstein remains confident in the company's fundamentals and views his hiccup as a long-term opportunity which is consistent with our own view of the stock. 

Bernstein has a price target of $788 versus the high price target of $800 and the consensus price target of $729. The consensus sentiment is bullish verging on strongly bullish with a  notable uptrend and both sentiment and the consensus price target over the past three months. At current price levels, the stock is fairly valued relative to the analyst community but we see this as the early stages of a buying opportunity.  The trend in the consensus estimate is upward and should continue upward even after the company reports earnings next.

Three Downgrades You Might Want To Buy 

A Lucky Opportunity In Clover Health

Clover Health (NASDAQ: CLOV) has been one of the higher profile and better-covered IPOs of the year but the luster is already fading. The company lowered its guidance and receives several downgrades that have price action just above the all-time low. JPMorgan is the latest to issue a downgrade and that to underweight from neutral so it is a truly bearish call. They cut the price target to $9 from $15 which assumes this stock is fairly priced trading as is. The take-away, for us, is that JPMorgan is still bullish on managed care companies like this one think this one is more of a risk because of poor visibility. In our view, Clover Health may provide a little more risk compared to its more established peers but it also provides more opportunity for capital gain. 

Three Downgrades You Might Want To Buy

Should you invest $1,000 in Big Lots right now?

Before you consider Big Lots, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Big Lots wasn't on the list.

While Big Lots currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Big Lots (BIG)2.6$45.95+5.3%2.61%6.51Hold$53.00
Clover Health Investments (CLOV)1.7$4.30-4.4%N/AN/ASell$9.00
Charter Communications (CHTR)2.7$679.30+1.3%N/A30.95Buy$807.55
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.